- Scope of the procurement
- Lot 1.1. BORTEZOMIB
- Lot 1.2. CARBOPLATIN
- Lot 1.3. CETUXIMAB
- Lot 1.4. CISPLATIN
- Lot 1.5. CYCLOPHOSPHAMIDE
- Lot 1.6. CYTARABINE
- Lot 1.7. DESFERRIOXAMINE
- Lot 1.8. DOCETAXEL
- Lot 1.9. DOXORUBICIN
- Lot 1.10. EPIRUBICIN
- Lot 1.11. FLUOROURACIL
- Lot 1.12. GANCICLOVIR
- Lot 1.13. GEMCITABINE
- Lot 1.14. INFLIXIMAB
- Lot 1.15. IRINOTECAN
- Lot 1.16. METHOTREXATE
- Lot 1.17. NIVOLUMAB
- Lot 1.18. OXALIPLATIN
- Lot 1.19. PACLITAXEL
- Lot 1.20. PEMBROLIZUMAB
- Lot 1.21. PERTUZUMAB
- Lot 1.22. RITUXIMAB
- Lot 1.23. TRASTUZUMAB SC
- Lot 1.24. TRASTUZUMAB four
- Lot 1.25. VINCRISTINE
- Lot 2. Aseptically Prepared Dose Banded Medicines
- Lot 3. CIVAS
- Lot 4. Patient Specific Chemotherapy
Section one: Contracting authority
one.1) Name and addresses
HealthTrust Europe LLP (HTE) acting as agent for the University Hospitals of Coventry and Warwickshire NHS Trust (“UHCW”)
19 George Road
Edgbaston, Birmingham
B15 1NU
Telephone
+44 08458875000
Country
United Kingdom
NUTS code
UK - United Kingdom
Internet address(es)
Main address
https://healthtrusteurope.bravosolution.co.uk
one.3) Communication
Access to the procurement documents is restricted. Further information can be obtained at
https://healthtrusteurope.bravosolution.co.uk
Additional information can be obtained from the above-mentioned address
Tenders or requests to participate must be submitted electronically via
https://healthtrusteurope.bravosolution.co.uk
Tenders or requests to participate must be submitted to the above-mentioned address
one.4) Type of the contracting authority
Ministry or any other national or federal authority
one.5) Main activity
Health
Section two: Object
two.1) Scope of the procurement
two.1.1) Title
Supply of Aseptically Prepared Dose Banded Medicines
Reference number
SF051571
two.1.2) Main CPV code
- 33600000 - Pharmaceutical products
two.1.3) Type of contract
Supplies
two.1.4) Short description
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.1.5) Estimated total value
Value excluding VAT: £3,500,000,000
two.1.6) Information about lots
This contract is divided into lots: Yes
Tenders may be submitted for all lots
The contracting authority reserves the right to award contracts combining the following lots or groups of lots:
one or more Lots
two.2) Description
two.2.1) Title
BORTEZOMIB
Lot No
1.1
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CARBOPLATIN
Lot No
1.2
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CETUXIMAB
Lot No
1.3
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CISPLATIN
Lot No
1.4
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CYCLOPHOSPHAMIDE
Lot No
1.5
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CYTARABINE
Lot No
1.6
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
DESFERRIOXAMINE
Lot No
1.7
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
DOCETAXEL
Lot No
1.8
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
DOXORUBICIN
Lot No
1.9
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
EPIRUBICIN
Lot No
1.10
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
FLUOROURACIL
Lot No
1.11
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
GANCICLOVIR
Lot No
1.12
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
GEMCITABINE
Lot No
1.13
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
INFLIXIMAB
Lot No
1.14
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
IRINOTECAN
Lot No
1.15
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
METHOTREXATE
Lot No
1.16
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
NIVOLUMAB
Lot No
1.17
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
OXALIPLATIN
Lot No
1.18
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
PACLITAXEL
Lot No
1.19
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
PEMBROLIZUMAB
Lot No
1.20
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
PERTUZUMAB
Lot No
1.21
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
RITUXIMAB
Lot No
1.22
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
TRASTUZUMAB SC
Lot No
1.23
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
TRASTUZUMAB IV
Lot No
1.24
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
VINCRISTINE
Lot No
1.25
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33692000 - Medical solutions
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £100,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Aseptically Prepared Dose Banded Medicines
Lot No
2
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33680000 - Pharmaceutical articles
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £500,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
CIVAS
Lot No
3
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33680000 - Pharmaceutical articles
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared, batch manufactured anti-cancer chemotherapy drugs in ready-to-administer presentations and agreed dose bands. The framework agreement will also cover the manufacturing and supply of patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £200,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
two.2) Description
two.2.1) Title
Patient Specific Chemotherapy
Lot No
4
two.2.2) Additional CPV code(s)
- 33600000 - Pharmaceutical products
- 33680000 - Pharmaceutical articles
- 85149000 - Pharmacy services
two.2.3) Place of performance
NUTS codes
- UK - United Kingdom
two.2.4) Description of the procurement
The Tender is to establish a framework agreement for the supply of a range of aseptically prepared patient specific chemotherapy. All chemotherapy doses will be based on the National Dose Banded Chemotherapy Standardised Product Specifications and National Dose Banding Tables, where a specification exists.
The duration of the framework agreement will be two (2) years initial period with the option of extending for up to twenty four (24) months, at HealthTrust Europe’s discretion.
two.2.5) Award criteria
Quality criterion - Name: Quality / Weighting: 60%
Price - Weighting: 40%
two.2.6) Estimated value
Value excluding VAT: £300,000,000
two.2.7) Duration of the contract, framework agreement or dynamic purchasing system
Duration in months
24
This contract is subject to renewal
Yes
Description of renewals
Framework can be extended for up to a period of 24 months at HealthTrust Europe`s discretion.
two.2.10) Information about variants
Variants will be accepted: No
two.2.11) Information about options
Options: No
two.2.13) Information about European Union Funds
The procurement is related to a project and/or programme financed by European Union funds: No
Section four. Procedure
four.1) Description
four.1.1) Type of procedure
Open procedure
four.1.3) Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement
Framework agreement with several operators
four.1.8) Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: Yes
four.2) Administrative information
four.2.2) Time limit for receipt of tenders or requests to participate
Date
14 February 2022
Local time
12:00pm
four.2.4) Languages in which tenders or requests to participate may be submitted
English
four.2.7) Conditions for opening of tenders
Date
14 February 2022
Local time
12:01pm
Section six. Complementary information
six.1) Information about recurrence
This is a recurrent procurement: No
six.3) Additional information
TERMS AND CONDITIONS / ACTIVITY BASED INCOME (ABI)
The terms and conditions of this Framework Agreement is appended to the ITT. These terms include provisions requiring the payment by the supplier of an ABI management charge in consideration of the award of this Framework Agreement, the management and administration by HTE of the overall contract structure and associated documentation, as well as the requirement to submit regular management information to HTE.
SUBMISSION OF EXPRESSIONS OF INTEREST AND PROCUREMENT INFORMATION.
This exercise will be conducted on the HTE Bravo portal. Candidates wishing to be considered must register expressions of interest as follows:
Register on the HTE portal at https://healthtrusteurope.bravosolution.co.uk. Login to the portal with username/password. Click the SQs/ITTs Open to All Suppliers link. These are the SQs/ITTs open to any registered supplier. Click on the relevant SQs/ITT to access the content. Click the Express Interest button at the top of the page. This will move the SQs/ITT into your My SQs/My ITTs page. You can access any attachments by clicking Buyer Attachments in the SQs/ITT Details box. Follow the onscreen instructions to complete the SQs/ITT. Submit your reply using the Submit Response button at the top of the page. If you
require any further advice, contact the Bravo e-Tendering Help Desk at help@bravosolution.co.uk.
Sid4Gov
HTE utilises the sid4gov supplier information database. Candidates should register on sid4gov at https://sid4gov.cabinetoffice.gov.uk/organisation/register and submit their sid4gov company profile for publication on the database. Candidates already registered on sid4gov must ensure information is up to date.
Where access to sid4gov is unavailable, please contact the sid4gov helpdesk at sid4gov@gps.gsi.gov.uk.
Please note that sid4gov does not prepopulate any fields of the SQ on HTE's Bravo Portal. Candidates must complete the Qualfication & Technical envelopes of the SQ on Bravo in full.
six.4) Procedures for review
six.4.1) Review body
Legal Department
19 George Road
Birmingham
B15 1NU
Country
United Kingdom